Comparison of two commercially available ELISAs for circulating sclerostin
- PMID: 24562839
- DOI: 10.1007/s00198-014-2635-3
Comparison of two commercially available ELISAs for circulating sclerostin
Abstract
This study investigates the performance and correlation of sclerostin measurements by two commercially available sclerostin ELISAs from TECOmedical and Biomedica. We found that the correlation between the results of two sclerostin assays is strong.
Introduction: Circulating sclerostin levels may provide insight into the pathophysiology of metabolic bone diseases such as osteoporosis. However, recent studies suggest that commercially available assays give different results. We compare the analytical performance of the two most used commercially available sclerostin ELISAs from TECOmedical and Biomedica.
Methods: Sclerostin levels were assessed in 20 paired serum, EDTA, and heparin plasma convenience samples from hospitalized patients. In addition, sclerostin was measured in serum samples from 34 patients with metabolic bone diseases and from 10 patients with chronic kidney disease (CKD). Samples from three healthy donors were used to determine stability and intra- and inter- assay precision.
Results: The average serum sclerostin concentration of all patients (n = 64) was 0.713 ± 0.58 ng/mL with the Biomedica assay and 0.734 ± 0.43 ng/mL with the TECO assay (p < 0.05). The results correlated strongly (r = 0.9; p < 0.0001), with Passing-Bablok regression showing a linear relationship but with a slight systematic and proportional difference between both assays. Sclerostin levels were about 30% higher in plasma than in serum for both assays, while no significant difference was seen between EDTA and heparin plasma. Intra- and inter- precision were <10% for TECO and <20% for Biomedica. Samples were stable for up to three freeze-thaw cycles with both assays.
Conclusions: The two commercially available ELISAs for measuring circulating levels of sclerostin are comparable. However, given the small but statistically significant systematic and proportional differences between both assays, results and reference ranges will be assay-specific. Results will also be specific to serum or plasma.
Similar articles
-
Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients.Discoveries (Craiova). 2016;4(1):e55. doi: 10.15190/d.2016.2. Discoveries (Craiova). 2016. PMID: 27088126 Free PMC article.
-
Can we compare serum sclerostin results obtained with different assays in hemodialysis patients?Int Urol Nephrol. 2015 May;47(5):847-50. doi: 10.1007/s11255-015-0971-7. Epub 2015 Apr 11. Int Urol Nephrol. 2015. PMID: 25862239
-
How Accurate is Your Sclerostin Measurement? Comparison Between Three Commercially Available Sclerostin ELISA Kits.Calcif Tissue Int. 2016 Jun;98(6):546-55. doi: 10.1007/s00223-015-0105-3. Epub 2016 Jan 9. Calcif Tissue Int. 2016. PMID: 26749312 Free PMC article.
-
Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.Nephrol Dial Transplant. 2015 Aug;30(8):1345-56. doi: 10.1093/ndt/gfv081. Epub 2015 Apr 7. Nephrol Dial Transplant. 2015. PMID: 25854266 Review.
-
[Wnt signaling and bone metabolic diseases.].Clin Calcium. 2019;29(3):329-336. doi: 10.20837/4201903329. Clin Calcium. 2019. PMID: 30814378 Review. Japanese.
Cited by
-
Sclerostin and CKD-MBD.Curr Osteoporos Rep. 2015 Jun;13(3):159-65. doi: 10.1007/s11914-015-0263-2. Curr Osteoporos Rep. 2015. PMID: 25691219 Review.
-
Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus.Bone Rep. 2020 May 11;12:100279. doi: 10.1016/j.bonr.2020.100279. eCollection 2020 Jun. Bone Rep. 2020. PMID: 32455152 Free PMC article.
-
Bone resorption following weight loss surgery is associated with treatment procedure and changes in secreted Wnt antagonists.Endocrine. 2016 Jul;53(1):313-21. doi: 10.1007/s12020-016-0903-z. Epub 2016 Mar 8. Endocrine. 2016. PMID: 26956843 Clinical Trial.
-
Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients.Discoveries (Craiova). 2016;4(1):e55. doi: 10.15190/d.2016.2. Discoveries (Craiova). 2016. PMID: 27088126 Free PMC article.
-
Can we compare serum sclerostin results obtained with different assays in hemodialysis patients?Int Urol Nephrol. 2015 May;47(5):847-50. doi: 10.1007/s11255-015-0971-7. Epub 2015 Apr 11. Int Urol Nephrol. 2015. PMID: 25862239
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources